Dr. Harvey Berger Discusses Ponatinib

Ariad Pharma CEO on Latest Leukemia Data from CNBC.

Dr. Harvey Berger discusses ponatinib, an oral drug developed by ARIAD to treat chronic myeloid leukemia(CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Ponatinib was designed to treat the resistant and tolerant forms of CML helping patients who have a mutation resistant to other cancer therapies.

ARIAD collaborators presented compelling clinical data about ponatinib at the American Society of Clinical Oncologists Meeting. Dr. Berger stated that “Well over one half of the patients who have failed every other CML drug, and had a very difficult time with their disease, now have a new treatment that will make a big difference in their lives.”

ARIAD collaborators presented compelling data about ponatinib and Dr. Harvey Berger has made numerous statements about this data at several points throughout the past few years. For instance, Dr. Berger stated, “Well over one half of the patients who have failed every other CML drug, and had a very difficult time with their disease, now have a new treatment that will make a big difference in their lives.”

Ponatinib was approved by the FDA on December 14, 2012, for patients with resistant or intolerant CML and Ph+ ALL. The approval was under the FDA Accelerated Approval program which required ARIAD to carry out additional studies. The FDA then granted full approval in 2016 that included a label update to Ponatinib.

 

Leave a Reply

Your email address will not be published. Required fields are marked *